The government has already asked the Chinese company to submit the necessary documents including phase III trial data of the vaccine

NEW DELHI, Jan 4: India on Sunday granted emergency approval to Bharat Biotech’s COVAXIN but faced questions from industry experts and opposition lawmakers after taking the step without publishing efficacy data for the homegrown coronavirus vaccine.